Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease (RODEO)

This study has been completed.
Sponsor:
Collaborators:
AstraZeneca
Haukeland University Hospital
Information provided by (Responsible Party):
Torbjorn Omland, University Hospital, Akershus
ClinicalTrials.gov Identifier:
NCT00929734
First received: June 26, 2009
Last updated: September 7, 2015
Last verified: September 2015
Results First Received: July 9, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Rosuvastatin
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Rosuvastatin Rosuvastatin: 10mg tablets, once daily in three months
Placebo Placebo: 1 tablet, once daily in three months

Participant Flow:   Overall Study
    Rosuvastatin   Placebo
STARTED   49   50 
COMPLETED   47   47 
NOT COMPLETED   2   3 
Lost to Follow-up                2                1 
Withdrawal by Subject                0                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Complete case population

Reporting Groups
  Description
Rosuvastatin Rosuvastatin 10mg tablet
Placebo Placebo tablet
Total Total of all reporting groups

Baseline Measures
   Rosuvastatin   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 47   47   94 
Age 
[Units: Years]
Mean (Standard Deviation)
 66  (5.5)   63  (6.6)   65  (6.1) 
Gender 
[Units: Participants]
     
Female   21   24   45 
Male   26   23   49 
BMI 
[Units: Kg/m^2]
Mean (Standard Deviation)
 23  (3.8)   24  (4.1)   24  (3.9) 
Systolic blood pressure 
[Units: mmHg]
Mean (Standard Deviation)
 131  (17.7)   135  (20.1)   133  (18.9) 
Diastolic blood pressure 
[Units: mmHg]
Mean (Standard Deviation)
 79  (8.4)   80  (10.3)   80  (9.4) 
Heart rate 
[Units: Beats/min]
Mean (Standard Deviation)
 68  (11.2)   67  (10.9)   67  (11.0) 
History of hypertension 
[Units: Participants]
     
Yes   12   11   23 
No   35   36   71 
History of asthma 
[Units: Participants]
     
Yes   9   13   22 
No   38   34   72 
Pack-years [1] 
[Units: Pack-years]
Mean (Standard Deviation)
 39  (16.1)   35  (15.5)   37  (15.8) 
[1] Number of packs of cigarettes smoked per day by the number of years the person has smoked
Current smoking 
[Units: Participants]
     
Yes   12   23   35 
No   35   24   59 
Haemoglobin 
[Units: G/dl]
Mean (Standard Deviation)
 14.1  (1.4)   14.0  (0.2)   14.0  (1.2) 
Estimated Glomerular Filtration Rate (eGFR) [1] 
[Units: Ml/min]
Mean (Standard Deviation)
 82.4  (19.6)   90.1  (29.4)   86.2  (25.1) 
[1] Renal function as calculated by the Cockcroft-Gault formula ((140- age) × bodyweight/serum creatinine) (× 0.85 for women))
Leucocyte count 
[Units: cells*10^9/L]
Mean (Standard Deviation)
 6.6  (1.4)   6.9  (1.7)   6.7  (1.6) 
High-sensitivity C-reactive protein [1] 
[Units: mg/L]
Median (Inter-Quartile Range)
 1.4 
 (0.8 to 3.7) 
 1.8 
 (1.0 to 4.4) 
 1.7 
 (0.8 to 3.8) 
[1] Acute-phase reactant used in cardiovascular risk assessment
Interleukin 6 
[Units: pg/mL]
Median (Inter-Quartile Range)
 4.1 
 (2.9 to 5.3) 
 3.4 
 (2.7 to 4.7) 
 3.7 
 (2.7 to 5.1) 
Glucose 
[Units: mmol/L]
Mean (Standard Deviation)
 5.0  (0.6)   5.1  (0.7)   5.0  (0.6) 
Cholesterol 
[Units: mmol/L]
Mean (Standard Deviation)
 5.5  (0.9)   5.7  (1.1)   5.6  (1.0) 
LDL-C 
[Units: mmol/L]
Mean (Standard Deviation)
 3.3  (0.8)   3.5  (0.9)   3.4  (0.9) 
HDL-C 
[Units: mmol/L]
Mean (Standard Deviation)
 1.8  (0.1)   1.8  (0.1)   1.8  (0.5) 
Triglycerides 
[Units: mmol/L]
Mean (Standard Deviation)
 1.0  (0.4)   1.1  (0.5)   1.1  (0.4) 
Forced expiratory volume at one second (FEV1) 
[Units: Liter]
Mean (Standard Deviation)
 1.4  (0.6)   1.5  (0.7)   1.4  (0.6) 
FEV1, % of predicted 
[Units: Percent predicted value]
Mean (Standard Deviation)
 48.3  (18.9)   52.1  (18.8)   50.2  (18.9) 
FEV1/FVC [1] 
[Units: Percent of FVC]
Mean (Standard Deviation)
 47  (13.8)   49  (11.8)   48  (12.8) 
[1] Forced vital capacity (FVC)
Antihypertensive treatment 
[Units: Participants]
     
Yes   12   10   22 
No   35   37   72 
Inhaled corticosteroids [1] 
[Units: Participants]
     
Yes   36   34   70 
No   11   13   24 
[1] including long acting beta agonists (LABA)
Long acting beta agonists 
[Units: Participants]
     
Yes   2   3   5 
No   45   44   89 
Long acting muscarinic antagonists 
[Units: Participants]
     
Yes   30   27   57 
No   17   20   37 
Anti-inflammatory treatment 
[Units: Participants]
     
Yes   2   0   2 
No   45   47   92 
Oestrogen treatment 
[Units: Participants]
     
Yes   4   3   7 
No   43   44   87 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Relative Change in Reactive Hyperemia Index (RHI)   [ Time Frame: Baseline to 3 months ]

2.  Secondary:   Relative Change in FEV1   [ Time Frame: Baseline to 3 months ]

3.  Secondary:   Relative Change in High-sensitivity C-reactive Protein   [ Time Frame: Baseline to 3 months ]

4.  Secondary:   Relative Change in Interleukin 6   [ Time Frame: Baseline to 3 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Professor Torbjørn Omland
Organization: University of Oslo
phone: +47 40107050
e-mail: torbjorn.omland@medisin.uio.no



Responsible Party: Torbjorn Omland, University Hospital, Akershus
ClinicalTrials.gov Identifier: NCT00929734     History of Changes
Other Study ID Numbers: 2009A2
Study First Received: June 26, 2009
Results First Received: July 9, 2015
Last Updated: September 7, 2015
Health Authority: Norway: Norwegian Medicines Agency
Norway: Data Protection Authority